Chronic wounds don’t make headlines the way cancer or heart disease do. They don’t have awareness months or celebrity advocates. And yet, for the Medicare population and the providers who care for them, chronic wounds represent one of the most persistent and costly challenges in American healthcare. They accumulate costs quietly, across dozens of visits, multiple care settings, and years of treatment—often without a clear endpoint in sight.
The financial burden is real, and it falls on everyone. Medicare absorbs a disproportionate share of wound care expenditures, given the prevalence of chronic wounds among elderly patients with diabetes, peripheral arterial disease, and other complex comorbidities. Providers face mounting documentation burdens and payment pressures under value-based care models. And patients themselves shoulder costs that rarely show up in any dataset: transportation to specialty clinics, out-of-pocket supplies, and the quiet toll of lost productivity and diminished quality of life.
What makes the chronic wound economic burden particularly difficult to address is how poorly it is understood. Wound care happens across inpatient hospitals, outpatient clinics, skilled nursing facilities, and home health agencies. That fragmentation means no single data source captures the full picture. Claims data tells us what was billed, not what was healed. Without structured clinical data, it is nearly impossible to determine which interventions work, which patients are at highest risk of complications, or where the system is wasting resources on low-value care.
This is where quality registries enter the picture. Systematic, clinical-level data collection is not just a compliance exercise. It is the foundation for understanding what chronic wound care actually costs, what it produces in terms of outcomes, and how providers can improve both. The argument this article makes is straightforward: you cannot reduce a burden you cannot measure. And right now, the tools to measure it are available to every wound care provider willing to use them.
Why Chronic Wound Treatment Drives Sustained, Compounding Costs
Most healthcare costs are episodic. A patient has a procedure, recovers, and the billing cycle closes. Chronic wounds don’t work that way. A diabetic foot ulcer, a venous leg ulcer, a pressure injury, or an arterial ulcer can persist for months or years, requiring ongoing clinical attention at every step. The cost isn’t a single event. It’s a slow accumulation that compounds over time.
Think about what a single chronic wound patient’s care trajectory might involve: regular skilled nursing visits for wound assessment and dressing changes, advanced wound dressings that cost significantly more than standard gauze, negative pressure wound therapy for wounds that aren’t responding to conventional treatment, periodic debridement procedures to remove non-viable tissue, and specialist consultations spanning wound care nurses, podiatrists, vascular surgeons, and infectious disease physicians. Each of those touchpoints carries its own cost. Multiplied across a treatment course measured in months, the total becomes substantial.
Comorbidity burden makes the picture significantly more complicated. The patients most likely to develop chronic wounds are also the patients with the most complex medical profiles. Diabetes impairs wound healing at the cellular level and dramatically increases the risk of infection. Peripheral arterial disease reduces the blood flow needed for tissue repair. Heart failure and obesity create additional physiological barriers to healing. These comorbidities don’t exist in isolation from the wound. They interact with it, prolong it, and drive additional healthcare utilization that is difficult to disentangle from wound-specific costs.
When a wound patient is hospitalized for sepsis, is that a wound care cost or an infectious disease cost? When a diabetic patient with a foot ulcer requires an emergency department visit, how much of that visit is attributable to the wound versus underlying glycemic instability? These questions aren’t merely academic. They matter enormously for how we measure and allocate the economic burden of chronic wound care, and they illustrate why administrative claims data alone is so insufficient for understanding the true cost of this patient population.
The resource intensity of wound care also extends to the clinical workforce. Wound care is a specialty that requires trained nurses, certified wound care specialists, and physicians who understand the nuanced interplay between wound etiology, patient comorbidities, and treatment selection. That expertise is not cheap, and in many markets, it is in short supply. When care is fragmented across settings without coordinated clinical oversight, resource utilization tends to be higher and outcomes tend to be worse. The economic case for better-coordinated, data-driven wound care is built on exactly this dynamic.
Who Actually Pays When Chronic Wounds Go Unresolved
Medicare is the dominant payer for chronic wound care in the United States, and that fact has significant implications. The patients most affected by chronic wounds—elderly individuals with diabetes, peripheral arterial disease, and limited mobility—are precisely the population that Medicare serves. When wound care costs escalate, it is largely the taxpayer-funded Medicare program that absorbs the impact.
CMS data and published analyses have consistently documented that wound care represents a substantial expenditure within Medicare, particularly for patients with diabetic foot complications and lower extremity vascular disease. Researchers including Dr. Caroline Fife and colleagues have published work examining the scope of wound care costs within Medicare, and those analyses make clear that the burden is significant and likely underestimated due to the fragmentation of care across settings. Readers seeking specific figures are encouraged to consult published research available through carolinefifemd.com and the US Wound Registry’s white papers at uswoundregistry.com, where documented data is presented with appropriate sourcing.
Providers face a different but equally real financial pressure. Under value-based payment models—including MIPS—practices that cannot demonstrate quality outcomes risk payment adjustments that directly affect their bottom line. Wound care is inherently complex to document. The clinical detail required to accurately capture wound size, wound type, healing trajectory, and treatment rationale is far more granular than what standard billing codes can convey. That documentation burden falls on clinical staff, consuming time and resources that might otherwise go toward direct patient care.
Practices that treat high proportions of complex wound patients also face a structural disadvantage under generic quality reporting frameworks. If the measures being reported don’t reflect the actual complexity of wound management, providers may appear to be underperforming when they are, in fact, delivering appropriate care to an extraordinarily difficult patient population. This is one of the core arguments for specialty-specific quality measures developed and reported through qualified clinical data registries.
Patients and their caregivers represent a third tier of financial burden that is almost entirely invisible in claims data. Out-of-pocket costs for wound care supplies, transportation to specialty clinics, and the time cost of frequent appointments add up in ways that meaningfully affect treatment adherence. A patient who cannot reliably access wound care—because of cost, transportation, or caregiver availability—is a patient whose wound is more likely to progress to a serious complication. The economic consequences of that progression, including hospitalization and potential amputation, ultimately circle back to the payer and provider. The financial burden is interconnected across all three stakeholders, even when the data systems used to track it treat them separately.
What Clinical Data Reveals That Claims Data Cannot
Here’s a fundamental problem with how the healthcare system currently understands wound care: the data it relies on most heavily is the wrong kind of data. Claims data is built for billing, not for clinical insight. It records procedure codes, diagnosis codes, and dates of service. It does not record wound size at the time of treatment, the specific type of wound being managed, the treatment protocol applied, or whether the wound was healing, stagnant, or deteriorating.
This matters enormously for understanding outcomes. Two patients with the same diagnosis code for a diabetic foot ulcer may have wounds that are completely different in terms of depth, area, infection status, and vascular supply. The treatment appropriate for one may be entirely inappropriate for the other. Claims data cannot distinguish between them. As a result, any analysis built on claims data alone will be unable to identify which interventions actually drive healing and which are being applied in contexts where they are unlikely to succeed.
Registry-based clinical data operates differently. A well-designed wound care registry captures structured clinical information at the point of care: wound measurements, wound classification, treatment type, healing milestones, and complications. Over time, that data accumulates into a resource that can answer questions claims data never could. Which patient profiles are most likely to achieve healing within a defined timeframe? Which interventions are associated with reduced amputation risk? Where does care variation exist, and does that variation correlate with outcome differences?
The US Wound Registry has demonstrated what this kind of systematic data collection makes possible. Through published white papers and research drawing on real-world wound care data, the registry has illuminated patterns in healing rates, care variation, and amputation risk that would be invisible in administrative data. The Alliance of Wound Care Stakeholders (AWCS), with which the US Wound Registry is affiliated, has engaged with CMS on wound care quality measure development—using registry-derived evidence to advocate for measures that reflect the actual clinical complexity of wound management.
This is not a theoretical benefit. It is a demonstrated one. When wound care providers contribute their clinical data to a structured registry, they are not simply fulfilling a reporting obligation. They are adding to a growing body of evidence that the entire field depends on to improve. The research generated from registry data informs guidelines, shapes quality measures, and ultimately influences how wound care is delivered and reimbursed across the healthcare system. That is a meaningful contribution with consequences well beyond any individual practice’s MIPS score.
How MIPS Creates a Direct Financial Stake in Wound Care Quality
For wound care providers and podiatrists who participate in Medicare, the Merit-based Incentive Payment System is not an abstract policy concern. It is a concrete financial mechanism that adjusts reimbursement up or down based on performance across quality, cost, and practice improvement categories. The connection between wound care quality and provider revenue is direct, measurable, and growing in significance as CMS continues to shift payment toward value-based models.
The challenge for wound care specialists is that many of the quality measures available through traditional MIPS reporting pathways were not designed with complex wound management in mind. Generic measures around preventive care or chronic disease management may be technically reportable by a wound care practice, but they don’t capture what actually matters in wound care: whether wounds are healing, whether amputations are being prevented, whether patients are receiving appropriate evidence-based interventions.
Qualified Clinical Data Registries (QCDRs) address this problem directly. A QCDR like the US Wound Registry is approved by CMS to develop and report specialty-specific quality measures that reflect the clinical realities of wound care. When providers report through a QCDR, they can demonstrate performance on measures that are meaningful to their patient population rather than defaulting to generic metrics that may not reflect the complexity of their practice. This matters both for the integrity of the quality measurement process and for the provider’s ability to demonstrate genuine value under MIPS.
Benchmarking is another significant advantage of registry-based MIPS reporting. When a practice’s outcome data is aggregated alongside data from other wound care providers across the country, it becomes possible to understand how that practice’s results compare to peers treating similar patient populations. That kind of comparative insight is foundational for quality improvement. Without a benchmark, a provider has no way to know whether a healing rate that feels acceptable is actually below what comparable practices are achieving, or whether an approach that seems standard is actually producing better results than the field average.
Practices that engage with registry-based reporting are, in effect, investing in the data infrastructure that supports continuous improvement. The MIPS financial incentive provides an entry point, but the value extends well beyond the annual payment adjustment. Providers who understand their outcomes in clinical detail are better positioned to make evidence-based decisions, reduce unnecessary variation, and ultimately deliver more cost-efficient care to their most complex patients.
The Case for Systematic Data as a Cost-Reduction Strategy
It’s worth being direct about something: better data collection does not automatically reduce costs. What it does is make cost reduction possible in ways that were previously not achievable. The mechanism runs through several channels, each worth examining.
The first is early identification of non-progressing wounds. When clinical data is tracked systematically over time, providers can identify wounds that are not responding to treatment within expected timeframes. That early signal enables timely escalation of care, whether that means a change in treatment protocol, a referral to a vascular specialist, or a more aggressive approach to infection management. The alternative, which is continuing a non-effective treatment until a crisis forces a change, is both clinically harmful and economically costly. Hospitalization for wound-related sepsis or emergency amputation is far more expensive than a well-timed escalation of outpatient care. Systematic tracking makes the former less likely.
The second channel is population-level evidence for guideline development. Registry data, aggregated across thousands of patients and providers, supports the kind of outcomes research that can identify which interventions produce healing and which do not. That evidence base is what allows professional societies and guideline developers to steer the field away from low-value interventions and toward protocols with demonstrated efficacy. Over time, this reduces waste in the system by shifting practice patterns toward approaches that are more likely to produce healing and less likely to generate costly complications.
The third channel is care coordination infrastructure. The US Wound Registry has developed a health information exchange (HIE) specifically designed for wound care, enabling clinical information to follow patients across care settings. When a patient transitions from a hospital to a skilled nursing facility to home health, wound care information that is captured in a structured, interoperable format can be shared with each subsequent provider. That continuity reduces redundant testing, prevents treatment gaps, and supports the kind of coordinated care that produces better outcomes at lower cost. Fragmented care is expensive care, and HIE infrastructure is one of the most practical tools available for reducing fragmentation.
None of these benefits are hypothetical. They are the logical and well-documented consequences of structured data collection applied to a clinical domain where data has historically been scarce. The investment required is real, but so is the return.
From Cost Awareness to Clinical Action: The Path Forward
The chain of logic in this article is worth stating plainly before closing. Chronic wounds carry a substantial and growing economic burden. That burden is poorly understood without high-quality clinical data. Registries are the mechanism for generating that data at the scale and granularity the field needs. And MIPS participation creates a financial incentive for providers to engage with registry infrastructure in a way that benefits both their practice and the broader system.
For wound care providers and podiatrists, the practical implication is clear. Joining a qualified clinical data registry is not merely a compliance exercise. It is an investment in the data infrastructure that makes better outcomes possible, for your patients, for your practice, and for a healthcare system that is struggling to understand and manage one of its most underrecognized cost drivers.
The US Wound Registry offers MIPS support, specialty-specific quality measures, published white papers on wound care outcomes, and health information exchange infrastructure designed specifically for wound care providers. These resources exist because the field needs them, and because the evidence generated through structured data collection has the potential to change how wound care is understood, delivered, and reimbursed.
If you are a wound care specialist or podiatrist who wants to understand how registry participation can support your practice, learn more about our services and explore the research and tools available through the US Wound Registry.
The Bottom Line on Chronic Wound Costs
The economic burden of chronic wounds is not inevitable. It is, in significant part, a consequence of fragmented care, inconsistent practice patterns, and a chronic shortage of the clinical data needed to identify what works and what doesn’t. Those are not fixed conditions. They are addressable ones, and the tools to address them are available now.
Providers who participate in structured quality reporting through a qualified clinical data registry are doing more than satisfying a CMS requirement. They are contributing to a data infrastructure that the entire field of wound care depends on to improve. Every wound measurement entered, every healing trajectory tracked, and every outcome documented adds to a growing body of evidence that researchers, guideline developers, and policymakers can use to make wound care more effective and more efficient.
The chronic wound economic burden is real, it is significant, and it is growing alongside an aging population with rising rates of diabetes and vascular disease. Reducing it requires better data, better coordination, and providers who are willing to engage with the systems that make both possible. That work starts at the practice level, with a decision to participate in the kind of structured quality reporting that turns clinical care into clinical evidence.
To learn how the US Wound Registry supports wound care providers and podiatrists with MIPS compliance, specialty-specific quality measures, and outcomes research, visit uswoundregistry.com and connect with our team.
Recent Comments